A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumors, Advanced Hematologic Tumors

In brief

A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.

Key facts

Study ID: NCT06188208
Run by: Vividion Therapeutics, Inc.
People needed: 132
Starts: 2024-01-05
Expected to finish: 2026-02-20
Last updated by the study team: 2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

California Research Institute — Los Angeles, California, United States
Florida Cancer Specialists — Sarasota, Florida, United States
Sarah Cannon Research Institute — Nashville, Tennessee, United States
NEXT Austin — Austin, Texas, United States
MDACC — Houston, Texas, United States
NEXT Dallas — Irving, Texas, United States
NEXT San Antonio — San Antonio, Texas, United States
University of Utah Huntsman Cancer Institute — Salt Lake City, Utah, United States
NEXT Virginia — Fairfax, Virginia, United States
Blacktown Hospital — Blacktown, New South Wales, Australia
Orange Health Service — Orange, New South Wales, Australia
Gold Coast University Hospital — Southport, Queensland, Australia
Cancer Research South Australia — Adelaide, Australia
ICON Cancer Research — South Brisbane, Australia
START Barcelona Hospital HM Nou Delfos — Barcelona, Spain
Vall d'Hebron — Barcelona, Spain
Hospital Universitario 12 de Octubre — Madrid, Spain
NEXT Madrid — Madrid, Spain
START Madrid CIOCC — Madrid, Spain
Start Madrid-FJD, Hospital Fundacion Jimenez Diaz — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.